LENSAR posts investor presentation highlighting ALLY robotic laser cataract surgery platform
LNSR•Quarterly results and operating metrics
- Q2 2026 revenue was $16.5 million, up 18% from Q2 2025.
- Recurring revenue was $13.69 million, up 20%.
- Gross margin was 59% in Q2 2026 versus 50% a year earlier.
- Net income was $3.54 million versus a $1.76 million loss.
- Cash and investments were $13.6 million at June 30, 2026 versus $20.3 million at June 30, 2025.
- U.S. procedure share rose to 23.4% in Q2 2026.
- The global installed base reached 445 systems, up 9% year over year.
Investor presentation highlights ALLY robotic cataract laser platform
LENSAR outlined its growth strategy around its ALLY robotic cataract laser system, targeting workflow efficiency, higher procedure conversion, and recurring revenue expansion.
